Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Nasopharyngitis, also known as common cold, is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes, or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache, and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

The nasopharyngitis (common cold) drugs in Development market report provides an overview of the Nasopharyngitis pipeline landscape. It provides comprehensive information on the therapeutics under development for Nasopharyngitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis and features dormant and discontinued projects.

What are the targets of the Nasopharyngitis pipeline drugs market?

The targets of the Nasopharyngitis pipeline drugs market are Alpha 1 Adrenergic Receptor, Glycylpeptide N Tetradecanoyltransferase, Histamine H1 Receptor, Mu Type Opioid Receptor, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.

Nasopharyngitis pipeline drugs market, by targets

Nasopharyngitis pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Nasopharyngitis pipeline drugs market?

The mechanisms of action of the Nasopharyngitis pipeline drugs market are Alpha 1 Adrenergic Receptor Agonist, Glycylpeptide N Tetradecanoyltransferase Inhibitor, Histamine H1 Receptor Antagonist, Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor.

Nasopharyngitis pipeline drugs market, by mechanisms of action

Nasopharyngitis pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Nasopharyngitis pipeline drugs market?

The routes of administration in the Nasopharyngitis pipeline drugs market are oral and nasal.

Nasopharyngitis pipeline drugs market, by routes of administration

Nasopharyngitis pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Nasopharyngitis pipeline drugs market?

The only molecule type in the Nasopharyngitis pipeline drugs market is small molecule.

Which are the key companies in the Nasopharyngitis pipeline drugs market?

Some of the key companies in the Nasopharyngitis pipeline drugs market are Adare Pharma Solutions, Charleston Laboratories Inc, Eurofarma Laboratorios SA, Firebrick Pharma Pty Ltd, Pfizer Inc, SaNOtize Research and Development Corp, SSP Co Ltd, and Tris Pharma Inc.

Nasopharyngitis pipeline drugs market, by key companies

Nasopharyngitis pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Alpha 1 Adrenergic Receptor, Glycylpeptide N Tetradecanoyltransferase, Histamine H1 Receptor, Mu Type Opioid Receptor, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2
Mechanisms of Action Alpha 1 Adrenergic Receptor Agonist, Glycylpeptide N Tetradecanoyltransferase Inhibitor, Histamine H1 Receptor Antagonist, Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor
Routes of Administration Oral and Nasal
Molecule Types Small Molecule
Key Companies Adare Pharma Solutions, Charleston Laboratories Inc, Eurofarma Laboratorios SA, Firebrick Pharma Pty Ltd, Pfizer Inc, SaNOtize Research and Development Corp, SSP Co Ltd, and Tris Pharma Inc

This report provides:

  • A snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • Reviews of pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Adare Pharma Solutions
Charleston Laboratories Inc
Eurofarma Laboratorios SA
Firebrick Pharma Pty Ltd
Pfizer Inc
SaNOtize Research and Development Corp
SSP Co Ltd
Tris Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasopharyngitis (Common Cold) – Overview

Nasopharyngitis (Common Cold) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nasopharyngitis (Common Cold) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasopharyngitis (Common Cold) – Companies Involved in Therapeutics Development

Adare Pharma Solutions

Charleston Laboratories Inc

Eurofarma Laboratorios SA

Firebrick Pharma Pty Ltd

Pfizer Inc

SaNOtize Research and Development Corp

SSP Co Ltd

Tris Pharma Inc

Nasopharyngitis (Common Cold) – Drug Profiles

(acetaminophen + fexofenadine + phenylephrine) – Drug Profile

Product Description

Mechanism Of Action

guaifenesin ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

hydrocodone bitartrate + Undisclosed drug – Drug Profile

Product Description

Mechanism Of Action

IMP-1088 – Drug Profile

Product Description

Mechanism Of Action

NORS-1002 – Drug Profile

Product Description

Mechanism Of Action

ORB-110 – Drug Profile

Product Description

Mechanism Of Action

History of Events

povidone iodine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit MAPK13 for Asthma and Cold – Drug Profile

Product Description

Mechanism Of Action

ST-HT – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRN-123 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRN-124 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TRN-125 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Nasopharyngitis (Common Cold) – Dormant Projects

Nasopharyngitis (Common Cold) – Discontinued Products

Nasopharyngitis (Common Cold) – Product Development Milestones

Featured News & Press Releases

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine

Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Nasopharyngitis (Common Cold), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Nasopharyngitis (Common Cold) – Pipeline by Adare Pharma Solutions, 2022

Nasopharyngitis (Common Cold) – Pipeline by Charleston Laboratories Inc, 2022

Nasopharyngitis (Common Cold) – Pipeline by Eurofarma Laboratorios SA, 2022

Nasopharyngitis (Common Cold) – Pipeline by Firebrick Pharma Pty Ltd, 2022

Nasopharyngitis (Common Cold) – Pipeline by Pfizer Inc, 2022

Nasopharyngitis (Common Cold) – Pipeline by SaNOtize Research and Development Corp, 2022

Nasopharyngitis (Common Cold) – Pipeline by SSP Co Ltd, 2022

Nasopharyngitis (Common Cold) – Pipeline by Tris Pharma Inc, 2022

Nasopharyngitis (Common Cold) – Dormant Projects, 2022

Nasopharyngitis (Common Cold) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Nasopharyngitis (Common Cold), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.